latest update:
[TrialBase DB]

trial summary · NCT07683325

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease

Trial record from the TrialBase DB dataset, status RECRUITING, condition Fibrostenotic Crohn's Disease, sponsored by Agomab Spain S.L.U.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07683325phase PHASE2enrollment 320start 2026-10-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD). The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.

Source record: https://clinicaltrials.gov/study/NCT07683325

Facts

registry idNCT07683325
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionFibrostenotic Crohn's Disease
sponsorAgomab Spain S.L.U.
sponsor classINDUSTRY
enrollment320
start date2026-10-30
primary completion2028-12-31
completion2029-06-30
results postednot reported

Conditions

  • Fibrostenotic Crohn's Disease

Interventions

  • Ontunisertib
  • Placebo

Countries

  • Serbia
  • United Kingdom
  • United States

Intervention types: DRUG

Work with this record